These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 18440230)

  • 1. Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart.
    Spurney CF; Knoblach S; Pistilli EE; Nagaraju K; Martin GR; Hoffman EP
    Neuromuscul Disord; 2008 May; 18(5):371-81. PubMed ID: 18440230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dystrophin Deficiency Causes Progressive Depletion of Cardiovascular Progenitor Cells in the Heart.
    Jelinkova S; Sleiman Y; Fojtík P; Aimond F; Finan A; Hugon G; Scheuermann V; Beckerová D; Cazorla O; Vincenti M; Amedro P; Richard S; Jaros J; Dvorak P; Lacampagne A; Carnac G; Rotrekl V; Meli AC
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34068508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for duchenne muscular dystrophy.
    Chun JL; O'Brien R; Song MH; Wondrasch BF; Berry SE
    Stem Cells Transl Med; 2013 Jan; 2(1):68-80. PubMed ID: 23283493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy.
    Wasala NB; Bostick B; Yue Y; Duan D
    Hum Mol Genet; 2013 Jul; 22(13):2634-41. PubMed ID: 23459935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined deficiency of dystrophin and beta1 integrin in the cardiac myocyte causes myocardial dysfunction, fibrosis and calcification.
    Elsherif L; Huang MS; Shai SY; Yang Y; Li RY; Chun J; Mekany MA; Chu AL; Kaufman SJ; Ross RS
    Circ Res; 2008 May; 102(9):1109-17. PubMed ID: 18340010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment.
    Betts CA; McClorey G; Healicon R; Hammond SM; Manzano R; Muses S; Ball V; Godfrey C; Merritt TM; van Westering T; O'Donovan L; Wells KE; Gait MJ; Wells DJ; Tyler D; Wood MJ
    Hum Mol Genet; 2019 Feb; 28(3):396-406. PubMed ID: 30281092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac dysfunction and pathology in the dystrophin and utrophin-deficient mouse during development of dilated cardiomyopathy.
    Chun JL; O'Brien R; Berry SE
    Neuromuscul Disord; 2012 Apr; 22(4):368-79. PubMed ID: 22266080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.
    Spurney CF; Guerron AD; Yu Q; Sali A; van der Meulen JH; Hoffman EP; Nagaraju K
    BMC Cardiovasc Disord; 2011 May; 11():20. PubMed ID: 21575230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular phenotype of the
    Szabó PL; Ebner J; Koenig X; Hamza O; Watzinger S; Trojanek S; Abraham D; Todt H; Kubista H; Schicker K; Remy S; Anegon I; Kiss A; Podesser BK; Hilber K
    Dis Model Mech; 2021 Feb; 14(2):. PubMed ID: 33619211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of reactive oxygen species in the hearts of dystrophin-deficient mdx mice.
    Williams IA; Allen DG
    Am J Physiol Heart Circ Physiol; 2007 Sep; 293(3):H1969-77. PubMed ID: 17573457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy.
    Au CG; Butler TL; Sherwood MC; Egan JR; North KN; Winlaw DS
    Int J Exp Pathol; 2011 Feb; 92(1):57-65. PubMed ID: 21121985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic analysis of dystrophin deficiency and associated changes in the aged mdx-4cv heart model of dystrophinopathy-related cardiomyopathy.
    Murphy S; Dowling P; Zweyer M; Mundegar RR; Henry M; Meleady P; Swandulla D; Ohlendieck K
    J Proteomics; 2016 Aug; 145():24-36. PubMed ID: 26961938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcellular localization of dystrophin isoforms in cardiomyocytes and phenotypic analysis of dystrophin-deficient mice reveal cardiac myopathy is predominantly caused by a deficiency in full-length dystrophin.
    Masubuchi N; Shidoh Y; Kondo S; Takatoh J; Hanaoka K
    Exp Anim; 2013; 62(3):211-7. PubMed ID: 23903056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved mitochondrial function in the hearts of sarcolipin-deficient dystrophin and utrophin double-knockout mice.
    Mareedu S; Fefelova N; Galindo CL; Prakash G; Mukai R; Sadoshima J; Xie LH; Babu GJ
    JCI Insight; 2024 Apr; 9(9):. PubMed ID: 38564291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced dimethylarginine degradation improves coronary flow reserve and exercise tolerance in Duchenne muscular dystrophy carrier mice.
    Garbincius JF; Merz LE; Cuttitta AJ; Bayne KV; Schrade S; Armstead EA; Converso-Baran KL; Whitesall SE; D'Alecy LG; Michele DE
    Am J Physiol Heart Circ Physiol; 2020 Sep; 319(3):H582-H603. PubMed ID: 32762558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of dystrophin deficient rats: a new model for Duchenne muscular dystrophy.
    Larcher T; Lafoux A; Tesson L; Remy S; Thepenier V; François V; Le Guiner C; Goubin H; Dutilleul M; Guigand L; Toumaniantz G; De Cian A; Boix C; Renaud JB; Cherel Y; Giovannangeli C; Concordet JP; Anegon I; Huchet C
    PLoS One; 2014; 9(10):e110371. PubMed ID: 25310701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exacerbation of dystrophic cardiomyopathy by phospholamban deficiency mediated chronically increased cardiac Ca
    Law ML; Prins KW; Olander ME; Metzger JM
    Am J Physiol Heart Circ Physiol; 2018 Dec; 315(6):H1544-H1552. PubMed ID: 30118340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy.
    Bostick B; Shin JH; Yue Y; Wasala NB; Lai Y; Duan D
    J Mol Cell Cardiol; 2012 Aug; 53(2):217-22. PubMed ID: 22587991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac CIP protein regulates dystrophic cardiomyopathy.
    He X; Liu J; Gu F; Chen J; Lu YW; Ding J; Guo H; Nie M; Kataoka M; Lin Z; Hu X; Chen H; Liao X; Dong Y; Min W; Deng ZL; Pu WT; Huang ZP; Wang DZ
    Mol Ther; 2022 Feb; 30(2):898-914. PubMed ID: 34400329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy.
    Dahiya S; Givvimani S; Bhatnagar S; Qipshidze N; Tyagi SC; Kumar A
    J Immunol; 2011 Sep; 187(5):2723-31. PubMed ID: 21810612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.